In 2020, CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals received FDA approval for Casgevy, the world's first CRISPR-based gene therapy, treating sickle cell disease. For the 100,000 Americans living with this debilitating genetic condition — and millions more worldwide — this represents a genuine cure, not just symptom management. For Muslim investors, it raises a profound question: Is investing in gene editing technology permissible in Islam?
This article examines the Shariah compliance of gene editing stocks like CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), and Beam Therapeutics (BEAM) through the lens of Islamic bioethics, a field that has been developing rapidly as biotechnology advances challenge traditional fiqh categories.
What is Gene Editing and How Does CRISPR Work?
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a technology that allows scientists to precisely edit DNA sequences inside living cells. Unlike older genetic engineering methods, CRISPR is fast, cheap, and remarkably accurate. It works by using a guide RNA to locate a specific genetic sequence, and a Cas9 enzyme to cut the DNA at that location, allowing researchers to delete, replace, or insert genetic material.
The applications are vast: correcting genetic mutations that cause disease, making crops more resistant to drought, creating disease-resistant livestock, and potentially enhancing human capabilities. The technology is so powerful — and so ethically fraught — that the 2020 Nobel Prize in Chemistry was awarded to its developers alongside urgent calls for regulatory oversight.
Islamic Bioethics and Genetic Modification: What Do Scholars Say?
Islamic jurisprudence does not have a single, unified position on gene editing. This is not because scholars have been negligent — it is because the technology raises genuinely novel ethical questions that classical fiqh did not anticipate. However, there are established principles that guide the discussion:
1. Necessity (darura) permits the prohibited: If a medical intervention can save a life or prevent serious harm, actions that would normally be questionable may become permissible. This principle has been invoked to permit organ transplants, blood transfusions, and other modern medical procedures.
2. Human dignity (karama) must be preserved: Islam teaches that human beings are created in the best of forms (ahsan taqweem). Any intervention that threatens human dignity or reduces people to biological material raises ethical red flags.
3. The intention (niyyah) matters: The purpose of genetic modification is ethically relevant. Curing disease is different from enhancement. Therapy is different from eugenics.
4. Germline vs. somatic editing: Editing the DNA of a person's body cells (somatic editing) affects only that individual. Editing reproductive cells (germline editing) changes the genome of future generations, raising far more serious ethical concerns.
The Scholarly Debate: Therapeutic Gene Editing
Most contemporary Islamic scholars — including those at the Islamic Fiqh Academy, the Fiqh Council of North America, and advisory boards in Malaysia and the Gulf — permit somatic gene therapy for serious, life-threatening diseases. The reasoning is straightforward: if the purpose is to cure or prevent illness, and the intervention does not involve other haram elements (like using embryonic stem cells obtained through abortion), then it falls within the principle of seeking medical treatment (tadawi), which the Prophet Muhammad ﷺ encouraged.
CRISPR Therapeutics' sickle cell treatment is a clear example: it edits the patient's own blood stem cells outside the body, then reinfuses them to produce healthy red blood cells. No embryos are harmed, no future generations are affected, and the result is a cure for a debilitating disease. Scholars who have examined this specific case generally classify it as permissible.
However, there are important caveats:
• The disease must be serious: Using CRISPR for cosmetic purposes (e.g., editing genes for eye color or height) would not meet the threshold of medical necessity and would likely be considered impermissible alteration of Allah's creation.
• Risks must be proportionate: Gene editing is still a young technology. If the risks of unintended mutations or off-target effects outweigh the benefits, the intervention may not be justified.
• Informed consent is essential: Islamic medical ethics require that patients fully understand what is being done to them and why.
The Red Line: Germline Editing and Enhancement
Where scholarly consensus breaks down is on germline editing — editing the DNA of embryos or reproductive cells so that changes are passed to future generations. This was the controversy behind the 2018 case of Chinese scientist He Jiankui, who used CRISPR to edit the genomes of twin girls to make them resistant to HIV. The global scientific community condemned the experiment, and He was sentenced to prison in China.
Islamic scholars have been similarly critical. The concern is not just technical (the risk of unintended harm to future generations) but ethical: germline editing raises the specter of eugenics, designer babies, and fundamentally altering what it means to be human. The Quranic verse "We have certainly created man in the best of stature" (Quran 95:4) is often cited to argue against enhancement editing.
Importantly, none of the publicly traded gene editing companies are currently focused on germline editing for reproductive purposes. CRISPR Therapeutics, Editas, Beam, and others are developing somatic therapies for existing patients. However, the potential for future pivots in business strategy is something Muslim investors should monitor.
Company-Specific Analysis
CRISPR Therapeutics (CRSP) - Sickle Cell and Beta-Thalassemia
Verdict: QUESTIONABLE (Scholarly Consultation Recommended)
CRISPR Therapeutics is the most advanced gene editing company, with an FDA-approved therapy (Casgevy) for sickle cell disease and beta-thalassemia. The business model is straightforward: develop gene therapies, conduct clinical trials, obtain regulatory approval, and generate revenue from treatment sales.
From a Shariah screening perspective, the company has no involvement in interest-based finance, alcohol, gambling, or pornography. The business activity itself — therapeutic gene editing — is generally permitted by scholars who have examined it.
However, there are two considerations that move CRSP into "questionable" territory rather than clear "halal":
1. Scholarly disagreement on gene editing: While many scholars permit therapeutic somatic gene editing, it is not a unanimous position. Some conservative scholars remain cautious about any form of genetic modification. If you follow a scholar or madhab with stricter views on biotechnology, you should seek a specific fatwa.
2. Future pipeline uncertainty: CRSP's current products are somatic therapies, but the company's research pipeline could expand. If they move into germline editing or enhancement technologies, the ethical calculus changes. Investors should monitor the company's R&D direction.
Editas Medicine (EDIT) - In Vivo Gene Editing
Verdict: QUESTIONABLE (Scholarly Consultation Recommended)
Editas develops CRISPR-based therapies for inherited diseases, with a focus on in vivo editing (editing genes directly inside the patient's body, rather than extracting cells). Their lead program targets Leber congenital amaurosis 10, a rare genetic blindness.
The same ethical framework applies: in vivo editing for serious disease is generally permissible under the principle of medical necessity. However, the technology is even newer and less proven than ex vivo (outside-the-body) editing, which raises questions about risk and benefit proportionality.
Editas is also pre-revenue and burning significant cash, which introduces financial risk independent of the halal question. The company's debt structure should be verified with a current screening tool before investing.
Beam Therapeutics (BEAM) - Base Editing
Verdict: QUESTIONABLE (Scholarly Consultation Recommended)
Beam Therapeutics uses base editing, a more precise form of gene editing that changes single DNA letters without cutting the double helix. The technology is potentially safer than traditional CRISPR, reducing the risk of unintended mutations.
Beam's pipeline includes therapies for sickle cell disease, liver diseases, and cancer. The business model is therapeutic, not enhancement, which aligns with permissible uses of gene editing under Islamic bioethics.
However, Beam is early-stage, with no approved products and significant financial uncertainty. The same caveats apply: consult a scholar familiar with Islamic bioethics, and monitor the company's R&D direction for any shift toward ethically problematic applications.
Investment Considerations Beyond Halal Status
Even if you conclude that gene editing stocks are permissible, they are extremely high-risk investments. Key considerations:
• Regulatory risk: Gene therapies face intense scrutiny from the FDA, EMA, and other regulators. A single safety issue can halt an entire pipeline.
• Clinical trial risk: Most gene editing companies are pre-revenue or early-revenue. If clinical trials fail, the stock can collapse.
• Pricing and reimbursement risk: Gene therapies are expensive (Casgevy costs $2.2 million per patient). Insurance companies and governments may push back on pricing, limiting revenue potential.
• Dilution risk: Biotech companies frequently raise capital by issuing new shares, diluting existing investors.
From an Islamic investment perspective, the principle of ghurur (excessive uncertainty) may be relevant. Speculative biotech stocks with unproven technologies may not be appropriate for conservative Muslim investors, even if the underlying science is permissible.
Practical Guidance for Muslim Investors
If you are considering gene editing stocks:
1. Seek scholarly guidance: Gene editing is a nuanced area of Islamic bioethics. Consult a scholar familiar with both fiqh al-muamalat and modern biotechnology. Organizations like the Fiqh Council of North America or the Islamic Medical Association of North America (IMANA) can provide resources.
2. Focus on therapeutic companies: Avoid companies exploring enhancement technologies, germline editing, or other ethically questionable applications. Stick to firms developing somatic therapies for serious diseases.
3. Monitor R&D pipelines: Gene editing companies can shift focus quickly. Track their clinical trial pipeline and research direction to ensure they remain within permissible boundaries.
4. Limit exposure: Gene editing stocks should be a small, speculative portion of a diversified portfolio. The sector is too volatile and uncertain for core holdings.
5. Verify current screening: Use a halal stock screener like Zoya or Musaffa to check debt ratios and revenue sources. Biotech companies often have complex financial structures.
Final Verdict: Gene Editing Stocks and Shariah Compliance
Therapeutic gene editing for serious diseases is generally permissible under Islamic bioethics, provided it meets the criteria of medical necessity, proportionate risk, and informed consent. Companies like CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics are developing somatic therapies that fall within this framework.
However, this is not a settled area of fiqh. Scholarly opinions vary, and the technology is evolving rapidly. Muslim investors should:
• Consult a qualified scholar before investing
• Monitor each company's R&D direction
• Avoid any firm pursuing germline editing or enhancement technologies
• Recognize the significant financial risk inherent in early-stage biotech
Gene editing represents a genuine medical breakthrough. But navigating it as a Muslim investor requires both diligence and humility — diligence in understanding what the companies are doing, and humility in recognizing when you need scholarly guidance to make an informed decision.
This article was originally published on ZakatInvest.com, a resource dedicated to helping Muslim investors navigate shariah compliant investing with clarity and integrity.